Mizuho Upgrades ACADIA Pharmaceuticals to Buy, Raises Price Target to $35
Portfolio Pulse from Benzinga Newsdesk
Mizuho analyst Uy Ear has upgraded ACADIA Pharmaceuticals (NASDAQ:ACAD) from Neutral to Buy and raised the price target from $20 to $35.
November 06, 2023 | 1:18 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ACADIA Pharmaceuticals has been upgraded from Neutral to Buy by Mizuho, with a raised price target from $20 to $35.
The upgrade from Neutral to Buy and the significant increase in price target by Mizuho indicates a positive outlook for ACADIA Pharmaceuticals. This could lead to increased investor interest and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100